BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma

NCT00039156 · clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Theradex